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1. Introduction
 
   Urinary tract infection (UTI) in women are more prevalent 
due to their short urethra and its anatomical proximity 
to the anal orifice[1,2]. UTIs are most common bacterial 
infection which complicates pregnancy[3]. Pregnancy causes 
numerous hormonal and mechanical changes in the body. 
Beginning in the sixth week, with peak incidence during 
22nd to 24th weeks, 90% of the pregnant females develop 
urethral dialatation increasing the risk of urinary stasis and 
vesicouretral reflux[4]. Further, glycosuria and aminoaciduria 
during pregnancy are additional factors to facilitate 
bacterial growth[5]. UTIs in pregnancy left untreated leads to 
maternal and perinatal morbidity and mortality[6]. Untreated 
bacteriruia during pregnancy is associated with low birth-
weight and premature delivery[7].
   Resistance development to previously effective antibiotics 
by the uropathogens has been reported globally in recent 
years[8,9], and their susceptibility vary from place and 
time[10]. There are two major challenges while treating 
UTIs in pregnancy; protection of fetus and resistance 
development of uropathogens. Physicians must consider 
possible side effects from drugs to protect maternal and 
fetal safety while prescribing antibiotics[11,12]. At the same 
time the chosen antibiotic should have efficacy and low 
resistance rates in a given population[13,14].
   Isolation of pathogens associated with UTIs and 
determining their antibiotic sensitive pattern will 






Objective: To determine the antibacterial profile of pregnant women with urinaty tract infections 
and analyze the antibiotic sensitivity pattern for the effective treatment. 
Methods: A total of 395 urine samples from pregnant women with different gestational age were 
processed for the isolation of uropathogens and tested against eight groups of antibiotics namely 
penicillins, cephalosporins, fluoroquinolones, aminoglycosides, macrolides, lincosamides, 
glycopeptides and sulfonamides. 
Results: A positive culture percentage of 46.6% was obtained with the highest urinary tract 
infection in third trimester gestational age. Among the uropathogens isolated, 85.6% were Gram 
negative and 14.4% were Gram positive with Escherichia coli as the predominant bacteria (43.9%) 
followed by Klebsiella oxytoca (19.4%) and Klebsiella pneumoniae (13.3%). Antibiotic sensitivity 
assay revealed that amikacin had the highest overall sensitivity (n=136; 76.7%) and the subsequent 
highest sensitivity was observed with ciprofloxacin (n=132; 73.3%), clindamycin (n=124; 68.9%), 
cefotaxime (n=117; 65%) and nalidixic acid (n=115; 63.9%). 
Conclusions: The findings revealed that uropathogens were more resistant to penicillins, 
macrolides and glycopeptides which restrict their use in treating urinaty tract infections during 
pregnancy. In conclusion, common causative bacteria and their antibiotic sensitivity pattern are 
to be determined along with their safety to mother and fetus for the effective treatment of urinary 
tract infections during pregnancy. 
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potentially reduce the inappropriate prescription of 
antibiotics and resistance development. Further, detection 
of changing susceptibility pattern by the uropathogens 
against commonly used antibiotics is one effective strategy 
for empirical treatment. This study evaluates the antibiotic 
susceptibility pattern of uropathogens from pregnancy. 
2. Materials and methods
2.1. Study population
   A total of 395 urine samples from pregnant women with 
or without having symptoms of UTI were collected during 
October 2012 to January 2014. The age of people included in 
the study ranged from 25-40 years. Verbal informed consent 
from target population and approval from institutional 
research ethical committee were obtained before starting the 
experiment.
2.2. Inclusion and exclusion criteria
   Female patients aged between 25-40 years with 
uncomplicated UTI symptoms like frequency, urgency and 
dysuria were included in the study. Pregnant women on 
antibiotics within the last 2 weeks and those who could not 
give consent to participate in the study were excluded.
2.3. Sample collection and processing
   Clean catch midstream urine samples were collected 
into a sterile screw capped universal container by standard 
method. The samples were labeled and 0.2 mg of boric acid 
was added to prevent the bacterial growth in urine samples. 
The samples were cultured on cysteine-lactose electrolyte 
deficient agar and blood agar using a sterile 4 mm platinum 
wired calibrated loop for the isolation of microorganisms. 
The plates were incubated for overnight at 37 °C and the 
samples were considered positive when an organism 
was cultured at a concentration of 104 CFU/mL which was 
estimated through multiplying the isolated colonies by 
1 000. The isolates were identified up to the species level by 
standard biochemical tests[15].
2.4. Antibiotic sensitivity assay
   Antibiotic sensitivity testing was performed by 
the  modi f ied  d isc  d i f fus ion  method  as  per  the 
recommendations[16]. Inoculums adjusted to 0.5 McFarland 
standard was swabbed on Mueller Hinton agar plates for 
antibiotic sensitivity assay. Eight groups of antimicrobials 
such as penicillins, cephalosporins, fluoroquinolones, 
aminoglycosides, macrolides, lincosamides, glycopeptides 
and sulfonamides were selected based on frequent 
prescription and used in this study. Among the group, the 
antibiotics tested were amoxicillin (10 µg), oxacillin (10 µg), 
cloxacillin (5 µg), cefotaxime (10 µg), ceftriaxone (30 µg), 
nalidixic acid (30 µg), ciprofloxacin (5 µg), norfloxacin (10 µg), 
amikacin (30 µg), gentamycin (10 µg), erythromycin (10 µg), 
clindamycin (2 µg), vancomycin (30 µg) and co-trimoxazole 
(30 µg). Statistical analysis was done using Chi-square test 
and student’s t-test.
3. Results
   Among the 395 samples collected, 180 were laboratory 
confirmed cases of UTI with a positive culture percentage of 
46.6% (Table 1). The age of the pregnant women ranged from 
25-40 years. Majority (50.6%) of the study participants were in 
the age group of 30-34 years. The highest UTI were observed 
at third trimester gestational age (n=103; 57.2%). 
Table 1
Characteristics of UTI in pregnant women.
Variables Numbers (n=180) Percentage
Age 25-29 years  87 48.3
30-34 years  91 50.6
≥35 years   2   1.1
Gestational period First trimester  21 11.7
Second trimester  56 31.1
Third trimester 103 57.2
   From the 180 isolates, 154 were Gram negative while 26 
were Gram positive bacteria (Figure 1). Escherichia coli (E. 
coli) was the most common organism isolated accounting for 
79 (43.9%) and the second highest organism was Klebsiella 
oxytoca (K. oxytoca) (n=35; 19.4%) followed by Klebiella 
pneumoniae (K. pneumoniae) (n=24; 13.3%). The other 
bacterial isolates obtained in the study were Enterococcus 
faecalis (E. faecalis), Staphylococcus saprophyticus (S. 
saprophyticus), Staphylococcus aureus (S. aureus), Proteus 
mirabilis (P. mirabilis), Proteus vulgaris (P. vulgaris), 
Pseudomonas aeruginosa (P. aeruginosa), Citrobacter koseri 
(C. koseri) and Citrobacter amalonaticus (C. amalonaticus). 
The frequency of occurrence of other bacterial isolates 
were E. faecalis (n=12; 6.7%), S. saprophyticus (n=10; 5.5%), 
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P. mirabilis (n=9; 5.0%), S. aureus (n=4; 2.2%), P. aeruginosa 
(n=3; 1.7%), P. vulgaris (n=2; 1.1%), C. koseri (n=1; 0.6%) and 


















Figure 1. Distribution of bacterial population in pregnant women with UTI.
   Antibiotic sensitivity pattern of the bacterial isolates 
revealed that E. coli with 89.9% sensitivity to amikacin, 
83.5% to co-trimoxazole, 79.7% to clindamycin and 77.2% 
to ciprofloxacin (Table 2). The antibiotics which had poor 
activity against E. coli were cloxacillin (13.9%), gentamycin 
(12.6%), vancomycin (8.9%), erythromycin (7.6%), amoxicillin 
(5.1%) and oxacillin (2.5%). K. oxytoca showed 88.5% 
sensitivity to ciprofloxacin and 62.8% to nalidixic acid while 
sensitivity to erythromycin was 0%. Most of the antibiotics 
were effective against K. pneumoniae with co-trimoxazole 
has significant activity (91.6%) followed by cefotaxime (83.3%). 
Gross 100% sensitivity was noted on nalidixic acid against E. 
faecalis and P. mirabilis. S. saprophyticus was 90% sensitive 
to co-trimoxazole and 80% to nalidixic acid, clindamycin 
and vancomycin. A complete 100% sensitivity to cefotaxime 
and clindamycin was observed with P. aeruginosa, P. 
vulgaris, C. koseri and C. amalonticus.
   The isolated uropathogens revealed the presence of high 
levels of single and multiple antimicrobial resistances 
against commonly prescribed drugs as shown in Table 
3. Amikacin had the highest overall sensitivity (n=138; 
76.7%) against the 180 isolates tested. This was followed 
by ciprofloxacin (n=132; 73.3%) and clindamycin (n=124; 
68.9%). Cefotaxime and nalidixic acid were exhibited 65.0% 
and 63.9% sensitivity against the isolates. Ceftriaxone had 
the overall sensitivity of 52.8%. The other antibiotics were 
recorded lesser than 50% of the sensitivity as follows: 
co-trimoxazole 45.0%, cloxacillin 31.6%, oxacillin 31.1%, 
norfloxacin 29.4%, vancomycin 28.9%, amoxicillin 28.3%, 
gentamycin 27.2% and erythromycin 18.3%.
Table 3
Antibiotic sensitivity pattern of the isolates.
Antibiotics Frequency Percentages 
Sensitive Resistance
Penicillin Amoxicillin  51 28.3 71.7
Oxacillin  56 31.1 68.9
Cloxacillin  57 31.6 68.4
Cephalosporin Cefotaxime 117 65.0 35.0
Ceftriaxone  95 52.8 47.2
Fluoroquinolones Nalidixic acid 115 63.9 36.1
Ciprofloxacin 132 73.3 26.7
Norfloxacin  53 29.4 70.6
Aminoglycosides Amikacin 138 76.7 23.3
Gentamycin  49 27.2 72.8
Macrolide Erythromycin  33 18.3 81.7
Lincosamides Clindamycin 124 68.9 31.1
Glycopeptide Vancomycin  52 28.9 71.1
Sulfonamide Co-trimoxazole  81 45.0 55.0
Table 2
Antibiotic sensitivity pattern of urinary isolates. n(%).
Antibiotic E. coli K. oxytoca K. 
pneumoniae
E. faecalis S. 
saprophyticus
P. mirabilis S. aureus P. 
aeruginosa
P. vulgaris C. koseri C. 
amalonticus
Amoxicillin (10 µg)  4 (5.1) 11 (31.4)  8 (33.3)  9 (75.0) 7 (70.0) 7 (77.7)  2 (50.0)  2 (66.6) 0 (0.0) 0 (0.0)   1 (100.0)
Oxacillin (10 µg)  2 (2.5) 12 (34.2) 16 (66.7)  9 (75.0) 7 (70.0) 6 (66.6)  1 (25.0)  2 (66.6) 0 (0.0) 0 (0.0)   1 (100.0)
Cloxacillin (5 µg) 11 (13.9)  8 (23.0) 10 (41.6) 11 (91.6) 3 (30.0) 8 (88.9)  3 (75.0)  1 (33.3)   1 (50.0) 0 (0.0)    1 (100.0)
Cefotaxime (10 µg) 53 (67.0) 17 (48.5) 20 (83.3)  7 (58.3) 4 (40.0) 8 (88.9)  1 (25.0)    3 (100.0)     2 (100.0)    1 (100.0)    1 (100.0)
Ceftriaxone (30 µg) 47 (59.5)  8 (22.8) 15 (62.5)  7 (58.3) 6 (60.0) 8 (88.9) 0 (0.0)  2 (66.6)   1 (50.0)    1 (100.0) 0 (0.0)
Nalidixic acid (30 µg) 38 (48.1) 22 (62.8) 17 (70.8)  12 (100.0) 8 (80.0)   9 (100.0)   3 (75.0)  2 (66.6)     2 (100.0)    1 (100.0)    1 (100.0)
Ciprofloxacin (5 µg) 61 (77.2) 31 (88.5) 11 (45.8)  8 (66.6) 6 (60.0) 8 (88.9)   2 (50.0)    3 (100.0)    1 (50.0)    1 (100.0) 0 (0.0)
Norfloxacin (10 µg) 45 (56.9) 10 (28.6) 14 (58.3)  9 (75.0) 4 (40.0) 6 (66.6)   1 (25.0)  2 (66.6)    1 (50.0)    1 (100.0)    1 (100.0)
Amikacin (30 µg) 71 (89.9) 18 (51.4) 19 (79.1)  9 (75.0) 5 (50.0) 8 (88.9)   3 (75.0)  2 (66.6)      2 (100.0) 0 (0.0)    1 (100.0)
Gentamycin (10 µg) 10 (12.6) 5 (14.2) 17 (70.8)  4 (33.3) 5 (50.0) 3 (33.3)   2 (50.0)  2 (66.6)     1 (50.0) 0 (0.0) 0 (0.0)
Erythromycin (10 µg)  6 (7.6)  0 (0.0)  7 (29.1)  5 (41.6) 7 (70.0) 4 (44.4)   3 (75.0) 0 (0.0)     1 (50.0) 0 (0.0) 0 (0.0)
Clindamycin (2 µg) 63 (79.7) 18 (51.4) 10 (41.6)  9 (75.0) 8 (80.0) 6 (66.6)   3 (75.0)    3 (100.0)       2 (100.0)    1 (100.0)    1(100.0)
Vancomycin (30 µg)  7 (8.9)  3 (56.0) 18 (75.0)  8 (66.6) 8 (80.0) 2 (22.2)     4 (100.0)   1 (33.3)      1 (50.0) 0 (0.0) 0 (0.0)
Co-trimoxazole (30 µg) 66 (83.5) 20 (57.1) 22 (91.6) 10 (83.3) 9 (90.0) 6 (66.6)    3 (75.0)     3 (100.0)       2 (100.0) 0 (0.0) 0 (0.0)
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4. Discussion
   While treating UTI in pregnancy, proper investigation 
and treatment are needed to prevent serious life 
threatening condition and morbidity rate[17]. In this study, 
it was observed that most of the uropathogens were same 
as over the years but the antibiotic resistance pattern 
were varying and increasing.
   Females of the age group between 25-34 years were 
more susceptible to UTIs (98.9%) than the elderly ones. 
High sexual activities, recent use of diaphragm with 
spermicide are associated with high incidence of UTI in 
young females[18]. The occurrence of asymptomatic and 
symptomatic bacteriuria was increased with gestational 
period as 31.1% in second trimester and 57.2% in third 
trimester.
   The Gram negative bacteria were predominated with E. 
coli being the most common pathogen (43.9%) followed by 
K. oxytoca (19.4%) in this study. E. coli and Klebsiella spp 
are most common in each of three trimesters of pregnant 
women with UTI[19]. Among the Gram positive organisms, 
E. faecalis and S. saprophyticus were formed the majority 
of uropathogens isolated. Enterococcus is reported as a 
frequent cause of UTIs[20]. S. saprophyticus has been found 
to colonize the urinary tract in earlier reports[21,22]. Most 
of the E. coli strains were sensitive to amikacin (89.9%) 
and similar kind of results was seen with Rizvi et al[23]. K. 
oxytoca was resistant to cefotaxime and ceftriaxone which 
is in accordance with earlier report where cephalosporin 
resistant strains were isolated from UTIs[24]. However, K. 
pneumoniae was highly sensitive to cefotaxime (83.3%) and 
the findings are similar with previous study[25]. Nalidixic 
acid and co-trimoxazole were highly effective against E. 
faecalis with 100% and 83.3% sensitivity. Cephalosporins 
and quinolones were shown to effective against UTI 
causing organisms in pregnant women[26].
   Antimicrobial susceptibility testing revealed the high 
resistance to penicillins (beta lactam group) by the 
urinary isolates and similar results were reported in 
earlier studies[27,28]. This could be a result of extensive 
usage of these antibiotics and increased spreading of beta 
lactamase producing strains. This finding restricts the 
use of beta lactam group of antibiotics though they are 
considered as traditional drugs safe in pregnancy. Most 
of the isolates had poor sensitivity to gentamycin (27.2%) 
which is known to be nephrotoxic[29], and should therefore 
be avoided. Previous report of trimethoprim as effective 
drug[30] against uropathogens is becoming less effective 
with only 45% sensitivity from this study. Sensitivity to 
flouroquinolones especially with ciprofloxacin (73.3%) 
and nalidixic acid (63.9%) were significant in this study 
thus revealing their potency against the uropathogens. 
However, widespread usage may lead to resistance against 
fluoroquinolones[31]. It was found that the resistance to 
amikacin and ciprofloxacin were low which suggests that 
these drugs may be considered as first line agents for 
treatment of UTIs among the pregnant women. Empirical 
use of antimicrobials may cause the development of 
more resistant bacteria which complicates the therapy in 
UTIs[32]. The results revealed that uropathogens were more 
resistant to penicillins, macrolides and glycopeptides 
which restrict their use in treating UTIs. 
   In conclusion, the susceptibility patterns of the urinary 
isolates suggest the necessity of sensitivity reports before 
initiation of antibiotic therapy in pregnant women with 
UTIs. Further, this data would help to formulate antibiotic 
prescription policies while treating pregnant women.
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